Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis 2 (Examination of the seasonal influence)

Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis 2 (Examination of the seasonal influence) - Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis 2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028635

Enrollment

Registered

2017-08-10

Start date

2017-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients(two weeks) the bath additive without sweat-antigen-inactivating and moisturizing ingredients(two wee

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with atopic dermatitis, whose treatment is no change within one month. 2.Patients who are 16 years old or older. 3.Patients who can visit our clinic reguraly. 4.4.Patients who participated in the clinical trial(Double-blind crossover trial to evaluate the efficacy and safety of the bath additive containing combination of sweat-antigen-inactivating and moisturizing ingredients for atopic dermatitis);passed more than two months after the examination end. 5.Patients who can agree in writing to this study.

Exclusion criteria

Exclusion criteria: 1. Patients who have unstable symptoms. 2. Patients who are treated with oral steroids and/or cyclosporine. 3.Patients who have history of hypersensitivity reactions to bath additive, cosmetics, food or etc. 4.Patients who use a product having the purpose of use like examination bath additive. 5.Patients judged inappropriate for this study by the physicians.

Design outcomes

Primary

Measure	Time frame
VAS for itch	—

Secondary

Measure	Time frame
Subjective symptom(disease questionnaire) Clinical condition(objective symptom: medical examination at the department of dermatology) Total assessment Safety	—

Countries

Japan

Contacts

Public ContactAkiko Kamegashira

Hiroshima University, Hiroshima, Japan Department of Dermatology

kamegash@yahoo.co.jp082-257-5238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026